Compare Figs Inc (FIGS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Figs Inc vs TG Therapeutics Inc — how do they compare? Figs Inc trades at $10.19 (market cap $1.66B), while TG Therapeutics Inc trades at $55.47 (market cap $8.64B). The key difference: TG Therapeutics Inc is far larger — about 5.2× Figs Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Figs Inc nearer its low. Which is the better fit depends on your goals.
| FIGS | TGTX | |
|---|---|---|
Market Cap | $1.66B | $8.64B |
Sector | Consumer Cyclical | Health |
52-Week High | $17.12 | $59.06 |
52-Week Low | $5.81 | $26.39 |
Enterprise Value | $1.44B | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIGS trades at $9.72, down 2.8% today, amid bearish technical signals despite recent earnings beats. Revenue grew to $631M in 2025 with a 66.6% gross margin, but net cash flow remains negative. Analyst consensus is bullish with a $19.50 price target, though technical indicators show selling pressure with RSI at neutral levels and ADX signaling a strong downtrend.
The stock presents a growth opportunity with strong fundamentals and analyst support, but faces near-term technical headwinds and margin pressures from tariffs and freight costs. Investors should weigh the 100% upside to consensus target against execution risks and persistent negative cash flow trends.
TG Therapeutics (TGTX) trades at $56.20, up 2.39% on the day, with a bullish technical signal and strong analyst consensus (84.6% buy ratings). The stock's momentum is supported by robust revenue growth, with 2025 revenue reaching $616.29M and net income of $447.18M, yielding impressive profitability margins (Gross Margin: 83.05%, ROE: 112.6%). Recent positive clinical updates for Briumvi in multiple sclerosis and schizophrenia trials have fueled investor optimism and media coverage.
The outlook remains positive due to Briumvi's commercial expansion and pipeline progress, though risks include earnings volatility (two recent misses), high valuation multiples (EV/EBITDA: 59.1), and clinical trial dependencies. The current price sits above the consensus price target of $48.50, suggesting near-term valuation concerns may limit upside unless operational execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
